Hims & Hers Health, Inc. $HIMS Shares Sold by Strong Tower Advisory Services

Strong Tower Advisory Services lessened its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 1.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,222 shares of the company’s stock after selling 384 shares during the period. Strong Tower Advisory Services’ holdings in Hims & Hers Health were worth $1,008,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the business. Nuveen LLC acquired a new position in Hims & Hers Health during the 1st quarter worth about $58,403,000. Yong Rong HK Asset Management Ltd boosted its holdings in Hims & Hers Health by 41.2% during the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after acquiring an additional 700,100 shares during the period. CloudAlpha Capital Management Limited Hong Kong purchased a new position in Hims & Hers Health during the 1st quarter valued at about $20,580,000. Jump Financial LLC boosted its holdings in Hims & Hers Health by 633.2% during the 1st quarter. Jump Financial LLC now owns 725,445 shares of the company’s stock valued at $21,437,000 after acquiring an additional 626,496 shares during the period. Finally, Northern Trust Corp boosted its holdings in Hims & Hers Health by 19.5% during the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after acquiring an additional 397,310 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HIMS. UBS Group set a $30.00 target price on Hims & Hers Health in a report on Monday, June 23rd. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Canaccord Genuity Group restated a “buy” rating and set a $68.00 target price on shares of Hims & Hers Health in a report on Friday, September 12th. Truist Financial lowered their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. Finally, Zacks Research lowered Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus target price of $38.92.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $53.98 on Friday. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a fifty-two week low of $17.36 and a fifty-two week high of $72.98. The firm has a market capitalization of $12.20 billion, a PE ratio of 67.48, a price-to-earnings-growth ratio of 3.93 and a beta of 2.25. The stock’s 50-day simple moving average is $50.86 and its 200-day simple moving average is $47.90.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same period last year, the business posted $0.06 EPS. Hims & Hers Health’s revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,637 shares of the firm’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $58.79, for a total transaction of $155,029.23. Following the sale, the insider owned 163,767 shares of the company’s stock, valued at approximately $9,627,861.93. This trade represents a 1.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Irene Becklund sold 8,410 shares of the firm’s stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $424,705.00. Following the transaction, the insider owned 1,418 shares in the company, valued at $71,609. This represents a 85.57% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,622,741 shares of company stock worth $83,695,469. 13.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.